BabyCue DiaCue rapid diagnostic test wins national challenge

BabyCue Private Limited, an Odisha-based healthtech startup, has won first prize at the Tribal Business Conclave Open Grand Challenge for its DiaCue rapid diagnostic test, which is designed to distinguish bacterial from non-bacterial diarrhoea in children under five. The award carries a cash prize of Rs 5 lakh and was presented by President Droupadi Murmu at Rashtrapati Bhavan in New Delhi.

The challenge was organised by the Ministry of Tribal Affairs in association with Startup India and the Department for Promotion of Industry and Internal Trade (DPIIT). The recognition puts a spotlight on a segment of India's diagnostics market that rarely gets national attention: low-cost, point-of-care tests built for primary and community health centres, where laboratory infrastructure is thin and treatment decisions are often made before test results arrive.

What exactly does DiaCue do?

DiaCue is a rapid diagnostic test that helps clinicians tell whether a child's diarrhoea is caused by a bacterial infection or something else. According to the company, the test delivers results in 15 to 20 minutes and is designed to work without complex laboratory equipment or cold-chain storage. That matters because conventional stool testing can take 24 to 48 hours, leaving doctors to decide on treatment while waiting. In the gap, antibiotics are often prescribed even when the infection is not bacterial.

According to the company, the founders, Manish Kumar Swain and Saumyashree Swain, began working on the problem during a BIRAC SPARSH Fellowship in 2022, spending time at primary and community health centres in rural Odisha. The company says healthcare workers there often had the clinical knowledge to treat patients but lacked quick diagnostic tools to identify the cause of diarrhoeal infections. BabyCue started developing DiaCue in 2024.

The company is incubated at KIIT Technology Business Incubator and has received support from the Technology Development Board under the Department of Science and Technology for its rapid diagnostic platform.

Why does a Rs 5 lakh prize matter for India's diagnostics market?

The cash itself is small. The signal is bigger. For a diagnostics startup, validation from a national challenge backed by the Ministry of Tribal Affairs, Startup India and DPIIT can open doors to pilot programmes, government partnerships and follow-on funding that are harder to access from outside the metro startup circuit.

India's point-of-care diagnostics market is still nascent but growing. Point-of-care testing refers to medical tests performed near the patient rather than in a central laboratory, usually with portable devices and quick turnaround. The segment has attracted attention in recent years as health brands look for products that can be sold or deployed beyond Tier-1 cities, where access to formal diagnostic labs is limited.

For health brands and investors, BabyCue's win illustrates a pattern: a startup that spends time in the field, identifies a specific clinical gap and builds a product around the constraints of that setting, rather than around what is easiest to sell in metros.

What can non-metro health startups learn from BabyCue?

BabyCue's path offers a few lessons for founders building in healthcare outside the big cities.

• Start with the workflow, not the technology. The founders identified that health workers lacked quick tests, not that they lacked clinical knowledge. The product was shaped around that gap.
• Design for the setting. DiaCue's claimed 15-to-20-minute turnaround and no cold-chain requirement are direct responses to the constraints of primary health centres. The company says the test works without complex lab equipment.
• Use fellowships and incubators as early validation. The BIRAC SPARSH Fellowship and KIIT incubation gave BabyCue field access and credibility before it had a commercial product.
• National challenges can be a distribution channel. The Tribal Business Conclave award connects the startup to a government ecosystem focused on tribal health, which could become an early deployment route.

For investors, the takeaway is that diagnostics innovation in India is not only about high-end pathology chains or at-home sample collection. Small, affordable tests that fit into a doctor's consultation can address large volumes of patients and reduce unnecessary antibiotic use, a public health priority.

What does this mean for consumer healthcare brands?

Consumer healthcare companies have spent the last few years pushing into prevention, wellness and at-home testing. DiaCue is not a consumer product in its current form; it is a clinical tool for health workers. But the underlying trend is the same: moving diagnostics closer to the patient.

If you run a health brand or a pharmacy chain, the question is whether similar low-cost tests could eventually be stocked or distributed through retail channels, or whether they will remain confined to public health programmes. That depends on regulatory approvals and on whether the company can scale manufacturing and distribution. No commercial launch details were available in the company's public statements.

The company's focus, as stated, remains on making diagnostic solutions more accessible so that a child's treatment does not have to depend on guesswork or delayed test results.

What should we watch next?

Three things will determine whether this award translates into market impact.

1. Regulatory progress. Diagnostic tests in India typically require regulatory clearance before they can be used in clinical settings.
2. Pilot deployments. The Tribal Business Conclave connects the company to the Ministry of Tribal Affairs ecosystem. Any pilot in tribal or rural health centres would be the first real-world test of the product's fit.
3. Funding and scale-up. The Rs 5 lakh prize is modest. The company's ability to raise further capital or secure government procurement will decide whether DiaCue reaches the health workers it was designed for.

For a diagnostics market that is often discussed in terms of big laboratory chains and digital health platforms, BabyCue's win is a reminder that some of the most consequential innovation is happening at the primary health centre level, one test at a time.